
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is well-positioned for future success due to their established leadership in the liquid biopsy market, their innovative testing technologies, and their potential for expansion into new areas. Combined with their successful collaborations and strong financial performance, the company's positive outlook is supported by their strong fundamentals.
Bears say
Guardant Health is set to face challenges in maintaining its high growth trajectory as competition in the liquid biopsy and precision oncology markets intensifies. Additionally, there is uncertainty surrounding the company's reimbursement dynamics, which could potentially pressure its ASPs. Despite its strong performance in the first quarter, issues with its MCED go-to-market strategy could limit growth in the future.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares